A UHPLC–MS/MS method for the quantitation of olmutinib in rat plasma

• Autorzy: Bao Su-su , Wen Jian , Liu Teng-hui , Zhang B. , Wang Chen-chen , Hu Guo-xin

Identyfikatory

DOI

10.1556/1326.2018.00375

• Języki publikacji: EN

Abstrakty

EN

Olmutinib (Olita™) is an oral third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) which is used to treat non-small cell lung cancer (NSCLC). A simple, rapid, and sensitive method based on ultra-performance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS) has been developed for the determination of olmutinib. Sample preparation was performed following simple one-step protein precipitation with acetonitrile. Olmutinib and internal standard (dasatinib) were separated on an Eclipse Plus C18 RRHD (2.1 × 50 mm, 1.8 μm) column. The mobile phase consisted of acetonitrile–0.1% formic acid in water with gradient elution. A total run time of 1.7 min was achieved. Detection was performed on a positive-ion electrospray ionization mass spectrometer in multiple reaction monitoring (MRM) mode, using transitions of m/z 487.2 → 402.1 for olmutinib and m/z 488.2 → 401 for dasatinib (IS), respectively. The calibration curve (R2 = 0.999) was linear over the range of 1–500 ng/mL. The recovery of olmutinib ranged from 85.8% to 95.5%. This method can be applied to pharmacokinetic studies of olmutinib.

Słowa kluczowe

EN

Olmutinib; UHPLC–MS/MS; pharmacokinetics; non-small cell lung cancer

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2019
• Tom: Vol. 31, no. 2
• Strony: 105--108
• Opis fizyczny: Bibliogr. 14 poz., rys., tab.

Twórcy

autor

Bao Su-su

• School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, China

autor

Wen Jian

• School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, China

autor

Liu Teng-hui

• School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, China

autor

Zhang B.

• School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, China

autor

Wang Chen-chen

• School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, China

autor

Hu Guo-xin

• School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, China

Bibliografia

• [1] Torre, L. A.; Bray, F.; Siegel, R. L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Ca-Cancer J. Clin. 2015, 65, 87–108.
• [2] Chen, W. Q.; Zhang, S. W.; Zou, X. N.; Zhao, P. Chin. J. Cancer Res. 2011, 23, 3–9.
• [3] D'Arcangelo, M.; Hirsch, F. R. Biol. Targets Ther. 2014, 8, 183–192.
• [4] Weiss, J. M.; Villaruz, L. C.; Socinski, M. A.; Ivanova, A.; Grilley-Olson, J.; Dhruva, N.; Stinchcombe, T. E. Lung Cancer 2014, 86, 288–290.
• [5] Shi, Y.; Au, J. S.; Thongprasert, S.; Srinivasan, S.; Tsai, C. M.; Khoa, M. T.; Heeroma, K.; Itoh, Y.; Cornelio, G.; Yang, P. C. J. Thorac. Oncol. 2014, 9, 154–162.
• [6] Filosto, S.; Becker, C. R.; Goldkorn, T. Mol. Cancer Ther. 2012, 11, 795–804.
• [7] Chou, Y. T.; Lin, H. H.; Lien, Y. C.; Wang, Y. H.; Hong, C. F.; Kao, Y. R.; Lin, S. C.; Chang, Y. C.; Lin, S. Y.; Chen, S. J.; Chen, H. C.; Yeh, S. D.; Wu, C. W. Cancer Res. 2010, 70, 8822–8831.
• [8] Laskin, J. J.; Sandler, A. B. Cancer Treat. Rev. 2004, 30, 1–17.
• [9] Glover, K. Y.; Perez-Soler, R.; Papadimitradopoulou, V. A. Semin. Oncol. 2004, 31, 83–92.
• [10] Haber, D. A.; Bell, D. W.; Sordella, R.; Kwak, E. L.; Godin-Heymann, N.; Sharma, S. V.; Lynch, T. J.; Settleman, J. Cold Spring Harbor Symp. Quant. Biol. 2005, 70, 419–426.
• [11] Peters, S.; Zimmermann, S.; Adjei, A. A. Cancer Treat. Rev. 2014, 40, 917–926.
• [12] Tan, C. S.; Gilligan, D.; Pacey, S. Lancet Oncol. 2015, 16, e447–e459.
• [13] Liao, B. C.; Lin, C. C.; Yang, J. C. Curr. Opin. Oncol. 2015, 27, 94–101.
• [14] Kim, E. S. Drugs 2016, 76, 1153–1157.

Uwagi

PL

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2019).